Cerebrolysin

It pairs the largest human trial base of any nootropic-adjacent peptide with an evidence story that independent reviewers do not confirm, plus a heavy infusion burden. If you are investigating acute neuro-recovery, severe stroke or moderate-to-severe brain injury, and you can access supervised clinic infusions and verified product, it is a reasonable thing to research with a clinician. If you are a healthy person hoping for a cognitive edge, the data is simply not there, and the effort and sourcing risk are high. The two real-world frictions that decide most cases are the IV or IM infusion burden and the grey-market sterility risk of an injectable biological.

✅ Best for: People investigating recovery from severe ischemic stroke, where the severe subgroup showed the clearest signal, who are working with a clinician. People dealing with moderate-to-severe traumatic brain injury who can access supervised infusion courses, since that is one of its better-supported uses, per Muresanu et al. 2020. Patients in countries where it is approved and supplied through a real pharmacy rather than imported. Anyone who can verify they have genuine EVER Pharma product and a clinical setting for sterile administration. Researchers and informed users who understand the evidence is split and want the recovery context, not an enhancement promise.

❌ Avoid if: You are a healthy person seeking cognitive enhancement, since there is no trial showing benefit in a well brain and the burden is high. You have a known allergy or hypersensitivity to biological or animal-derived products, given the foreign-protein anaphylaxis risk. You have active or suspected cancer, where a growth-factor-mimicking biological is unwise without specialist guidance. You cannot source verified product and would be relying on grey-market vials, because sterility, cold-chain, and counterfeit risk for an injectable can exceed the compound's own risk. You want a low-effort routine, because repeated multi-week clinic infusions are the opposite of that.